Literature DB >> 29356172

Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.

F Anzengruber1,2, M Drach1,2, J-T Maul1,2, A G Kolios1,2,3, B Meier1,2, A A Navarini1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29356172     DOI： 10.1111/jdv.14808

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

1.  Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.

Authors:  L J van Vugt; J M P A van den Reek; E Meulewaeter; M Hakobjan; N Heddes; T Traks; K Kingo; M Galluzzo; M Talamonti; J Lambert; M J H Coenen; E M G J de Jong
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-08-05       Impact factor: 6.166

Review 2.  Pharmacogenetics Update on Biologic Therapy in Psoriasis.

Authors:  Ester Muñoz-Aceituno; Luisa Martos-Cabrera; María Carmen Ovejero-Benito; Alejandra Reolid; Francisco Abad-Santos; Esteban Daudén
Journal:  Medicina (Kaunas)       Date:  2020-12-20       Impact factor: 2.430

3.  Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis.

Authors:  Danyi Zhang; Jianing Qiu; Xing Liao; Yi Xiao; Minxue Shen; Yaxiong Deng; Danrong Jing
Journal:  Front Med (Lausanne)       Date:  2022-01-25

Review 4.  Towards Personalized Medicine in Psoriasis: Current Progress.

Authors:  Elisa Camela; Luca Potestio; Angelo Ruggiero; Sonia Sofia Ocampo-Garza; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.